Autolus Therapeutics (NASDAQ:AUTL) Receives "Outperform" Rating from William Blair

Key Points

• William Blair has reaffirmed its "outperform" rating for Autolus Therapeutics (NASDAQ:AUTL), indicating confidence in the company's future performance.
• Autolus Therapeutics recently reported better-than-expected earnings with a loss of $0.18 per share, surpassing estimates, and a revenue of $13.50 million.
• The stock currently has an average rating of "Buy" from analysts, with an average target price set at $9.12.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "outperform" rating reaffirmed by William Blair in a research report issued to clients and investors on Wednesday,RTT News reports.

Other equities analysts also recently issued research reports about the company. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, July 21st. Finally, Wells Fargo & Company cut their target price on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $9.12.

Autolus Therapeutics Stock Up 1.9%

NASDAQ:AUTL traded up $0.03 on Wednesday, hitting $1.38. The stock had a trading volume of 858,714 shares, compared to its average volume of 2,193,899. The business's 50-day simple moving average is $1.89 and its two-hundred day simple moving average is $1.80. The stock has a market cap of $365.94 million, a price-to-earnings ratio of -1.64 and a beta of 1.87. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analysts' expectations of $12.92 million. As a group, equities research analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $26,000. Marex Group plc purchased a new position in shares of Autolus Therapeutics in the second quarter valued at approximately $28,000. R Squared Ltd purchased a new position in shares of Autolus Therapeutics in the second quarter valued at approximately $50,000. Delaney Dennis R purchased a new position in Autolus Therapeutics during the second quarter worth approximately $55,000. Finally, Forefront Wealth Management Inc. purchased a new position in Autolus Therapeutics during the second quarter worth approximately $61,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.